MRKMerck Sharp & Dohme LLCSigning up patients
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 614 (planned)
- Started
- Dec 15, 2023
- Main results expected
- Jan 25, 2028
- Fully finished
- May 27, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 49 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06170788 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC